Roughly half of Partners Group's revenue rests on the one thing an alternative asset manager controls almost entirely by itself: the valuation of illiquid positions inside its evergreen funds. That is the point of failure a new short report attacks, and it is why the accusation is more dangerous than the usual sell-side skepticism about a private-markets multiple. The claim is not that Partners Group paid too much for assets. The claim is that the reported value of those assets does not match what the same companies disclose in their own national filings. If even a fraction of that holds, the problem is not a valuation debate. It is a disclosure problem, and disclosure problems are the ones that break fundraising.
Why the Marks Are the Business
Evergreen funds are the growth story here. They contribute close to half of company revenue and they carry a structural feature that makes valuation integrity load-bearing rather than academic: investors subscribe and redeem at net asset value on an ongoing basis, not at exit. In a traditional closed-end drawdown fund, a stale or aggressive interim mark eventually gets trued up when the asset is sold and cash changes hands. In an open-ended evergreen structure, the mark itself is the transaction price. An investor buying in today pays the reported NAV; an investor redeeming today receives it. The valuation is not an estimate that resolves later. It is the money.
That is the mechanism the short thesis exploits. The report, covering roughly US$184.9 billion in assets under management and focused on the group's Master Fund, alleges that close to 40% of the evergreen funds' investments may be severely mismarked. In a drawdown vehicle that would be an argument about eventual returns. In an evergreen vehicle it is an argument about whether current subscribers and redeemers are transacting at the right price, and whether the reported revenue built on those NAVs is real. Management fees and any NAV-linked economics compound directly off the number under dispute.
The Filing Discrepancy Consensus Is Not Pricing
The single most damaging item in the report is not a valuation multiple. It is a share count. The Master Fund's largest Asia-Pacific holding is alleged to report roughly 50 million fewer shares of its key investment to the SEC than it reports to the Hong Kong Companies Registry, inside a position described as worth $322 million. This is the disclosure the guided narrative cannot smooth over, because it is not a matter of judgment. Two regulators receive two different numbers. One of them is wrong, and the reconciliation is either trivial or it is not available.
Sitting alongside it is an allegation with no valuation-theory defense at all: a Russian pharmaceutical equity marked up during the very reporting window in which the Russian state seized the asset by decree. A markup on an expropriated asset is not an aggressive assumption about growth. It is a mark moving in the opposite direction of the only fact that mattered in that window. These two items are qualitatively different from a rich EBITDA multiple. A multiple is arguable. A seized asset carried higher, and a share count that contradicts a public registry, are the kind of specifics that survive a rebuttal built on methodology.
When Marks and Operating Performance Point Opposite Directions
The valuation cases in the report share one shape: the direction of the mark and the direction of the business disagree.
The report alleges a 176.9% markup on a Swedish data-center operator, Green DC AB, over a window in which its revenue fell 18% and operating losses widened 42%. It alleges an 857.8% common-equity markup on a Portuguese biocontrol group, Rovensa, whose revenue grew 2.9% year over year, a growth rate that cannot carry an eightfold equity move on its own. It cites a position whose common equity jumped 383% in 26 days. And it names specific software holdings, Forterro and Unit4, inside a private-credit and equity book where the marks are the disputed object.
The unifying claim is that where multiples could be backed out, Partners Group applied marks sometimes more than twice the level independently commissioned valuation experts assigned. That is the difference between optimism and something harder to defend. Optimism uses an aggressive but defensible multiple on real numbers. The report's allegation is that the multiples themselves sit far outside the comparable range, and that common-equity values moved by hundreds of percent on operating results that did not.
The direct-debt book carries its own version of the pattern. Reported principal balances are alleged to have moved in ways inconsistent with standard senior-loan accounting, with principal and fair value moving by hundreds of percent and, in cases, in opposite directions. For a senior loan, principal amortizes on a schedule and fair value tracks credit quality and rates. Large moves in opposite directions are not how the instrument behaves. Separately, the report challenges a specific disclosure: Partners Group's claim that its private-credit software exposure is "less than half the industry average," against an estimated actual exposure of 32% in the available sample, which the report places above the industry average and above scrutinized peers such as Blue Owl.
The company's own reported operating economics are not in dispute here, and that gap is the whole point. Strong headline margins at the manager level tell you nothing about whether a specific fund's underlying marks reconcile with the portfolio companies' national filings. Consensus anchors to the group's profitability and its evergreen growth. The blind spot is the reconciliation the filings either support or do not.
What Would Break the Thesis
The counterargument deserves a fair statement, because private-markets valuation genuinely does diverge from public-filing snapshots for defensible reasons. Local statutory filings often use different accounting bases, different reporting entities, and different dates than a fund's fair-value framework. A markup can be justified by a subsequent financing round that reset the reference price regardless of trailing revenue. A share-count difference can reflect a holding-company layer, a class distinction, or a timing mismatch between two registries. The 383%-in-26-days move could be a recapitalization or a conversion event rather than a fabricated jump. None of these possibilities are exotic; they are the ordinary texture of private-markets reporting, and a short report is structurally incentivized to present the least charitable reading of each.
So the thesis breaks in a specific, checkable way. If Partners Group can produce the reconciliations, the financing events that reset each disputed mark, the entity and class explanations for the share-count gap, the seizure treatment showing an offsetting writedown elsewhere, then the report collapses into a methodology dispute the company wins. The items that do not survive that test are the ones with no valuation-theory defense: the mark on the expropriated Russian asset, and the two-regulator share-count discrepancy. Those either reconcile on paper or they do not, and no multiple argument reaches them.
The Observable Condition That Decides This
The market consequence the report targets is fundraising, and it is the right target. Evergreen fundraising depends on continuous investor confidence that NAV equals value, because subscriptions and redemptions clear at NAV every period. A closed drawdown fund can absorb a valuation controversy because the capital is already committed. An open evergreen fund cannot, because redemption is always available and the reported price is the redemption price. A credible mismarking allegation therefore does not need to be proven in full to do damage; it needs only to slow net inflows and quicken redemptions in the funds that produce half the revenue.
Watch the flows, not the rebuttal. A detailed methodological response from Partners Group is the expected move and proves little on its own. What matters is whether net evergreen subscriptions hold in the reporting periods after the allegation circulates, and whether an independent auditor or regulator engages the specific reconciliation items rather than the general methodology. Until the share-count discrepancy and the expropriated-asset markup are reconciled on the record, the cleaner reading is that the disputed marks carry real fundraising risk regardless of how the multiple debate resolves. The valuation is the product, and the product is what is being questioned.
